4142:TPE
Adimmune Corp
16,65 TWD
arrow_downward
-0,89%(-0,15) 1D
16-ноя., 11:09:42 GMT+8 · TWD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4142...
Open
16,80 TWD
High
17,00 TWD
Low
16,65 TWD
Mkt. cap
7,15 млд
Avg. vol.
1,12 млн
Volume
289,31 миң
52-wk high
22,50 TWD
52-wk low
15,65 TWD
EPS
-0,34 TWD
Shares outstanding
235,29 млн
No. of employees
564
Open
16,80 TWD
High
17,00 TWD
Low
16,65 TWD
Mkt. cap
7,15 млд
Avg. vol.
1,12 млн
Volume
289,31 миң
52-wk high
22,50 TWD
52-wk low
15,65 TWD
EPS
-0,34 TWD
Shares outstanding
235,29 млн
No. of employees
564
News stories
From web sources and news partners
investingLive
·
1 саат мурун
Morgan Stanley goes max overweight global stocks, sees 15% S&P 500 upside on AI capex
Yahoo Finance
·
1 саат мурун
Dow, S&P 500, Nasdaq Futures Edge Lower As Markets Brace For Nvidia Earnings, Anthropic IPO, Fed Minutes: SMMT, NBIS, HELP, MSTR In Focus
The Motley Fool
·
8 саат мурун
This Dividend King Yields 5 Times the S&P 500. Is It a Buy Now?
BigGo Finance
·
14 саат мурун
Goldman Sachs Sets 8,700 S&P 500 Target for 2027, Sees 14% Upside as AI Capex Peaks
Profile
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
About Adimmune Corp